The selected 49 applications are from 33 companies. Out of these 33 companies, 13 are Micro, Small and Medium Enterprises (MSMEs) besides some newly incorporated entities
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Subscribe To Our Newsletter & Stay Updated
